share_log

Biodexa Pharmaceuticals | 424B3: Prospectus

Biodexa Pharmaceuticals | 424B3: Prospectus

Biodexa Pharmaceuticals | 424B3：募資說明書
美股sec公告 ·  05/29 21:08
牛牛AI助理已提取核心訊息
Biodexa Pharmaceuticals PLC, a company listed on NASDAQ under the symbol BDRX, has filed a prospectus supplement with the Securities and Exchange Commission (SEC) on May 29, 2024. This filing amends and supplements the prospectus dated December 18, 2023, related to the offering of Class A and Class B Units. The Class A Units consist of American Depositary Shares (ADSs), Series E Warrants, and Series F Warrants, while the Class B Units include Pre-Funded Warrants, Series E Warrants, and Series F Warrants, along with Representative Warrants. The company has also filed a Form 6-K, reporting the closing of a transaction with accredited investors who exercised their existing Series E and Series F Warrants, resulting in the issuance of replacement Series G and Series H Warrants. The transaction generated approximately $6.05 million in gross proceeds for Biodexa Pharmaceuticals before expenses. Additionally, placement agent warrants were issued to Ladenburg Thalmann & Co., Inc. The company's ADSs, representing ordinary shares, closed at $1.08 on the NASDAQ Capital Market on May 28, 2024.
Biodexa Pharmaceuticals PLC, a company listed on NASDAQ under the symbol BDRX, has filed a prospectus supplement with the Securities and Exchange Commission (SEC) on May 29, 2024. This filing amends and supplements the prospectus dated December 18, 2023, related to the offering of Class A and Class B Units. The Class A Units consist of American Depositary Shares (ADSs), Series E Warrants, and Series F Warrants, while the Class B Units include Pre-Funded Warrants, Series E Warrants, and Series F Warrants, along with Representative Warrants. The company has also filed a Form 6-K, reporting the closing of a transaction with accredited investors who exercised their existing Series E and Series F Warrants, resulting in the issuance of replacement Series G and Series H Warrants. The transaction generated approximately $6.05 million in gross proceeds for Biodexa Pharmaceuticals before expenses. Additionally, placement agent warrants were issued to Ladenburg Thalmann & Co., Inc. The company's ADSs, representing ordinary shares, closed at $1.08 on the NASDAQ Capital Market on May 28, 2024.
Biodexa Pharmicals PLC是一家在納斯達克上市的公司，股票代碼爲BDRX，已於2024年5月29日向美國證券交易委員會（SEC）提交了招股說明書補充文件。本文件修訂並補充了2023年12月18日與A類和B類單位發行有關的招股說明書。A類單位包括美國存托股票（ADS）、E系列認股權證和F系列認股權證，而B類單位包括預融資認股權證、E系列認股權證和F系列認股權證以及代表性認股權證。該公司還提交了6-K表格，報告了與行使現有E系列和F系列認股權證的合格投資者完成的交易，最終發行了替代的G系列和H系列認股權證。該交易爲Biodexa Pharmicals帶來了約605萬美元的未計支出總收益。此外，向拉登堡塔爾曼公司發行了配售代理認股權證。該公司代表普通股的ADS於2024年5月28日在納斯達克資本市場收於1.08美元。
Biodexa Pharmicals PLC是一家在納斯達克上市的公司，股票代碼爲BDRX，已於2024年5月29日向美國證券交易委員會（SEC）提交了招股說明書補充文件。本文件修訂並補充了2023年12月18日與A類和B類單位發行有關的招股說明書。A類單位包括美國存托股票（ADS）、E系列認股權證和F系列認股權證，而B類單位包括預融資認股權證、E系列認股權證和F系列認股權證以及代表性認股權證。該公司還提交了6-K表格，報告了與行使現有E系列和F系列認股權證的合格投資者完成的交易，最終發行了替代的G系列和H系列認股權證。該交易爲Biodexa Pharmicals帶來了約605萬美元的未計支出總收益。此外，向拉登堡塔爾曼公司發行了配售代理認股權證。該公司代表普通股的ADS於2024年5月28日在納斯達克資本市場收於1.08美元。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。